Effect of omalizumab in health care workers with occupational latex allergy [5]

Journal of Allergy and Clinical Immunology

Volumn 113, Issue 2, 2004, Pages 360-361

  Leynadier, Francisque ^a   Doudou, Ouafia ^a   Gaouar, Hafida ^a   Le Gros, Vincent ^b   Bourdeix, Isabelle ^b   Guyomarch Cocco, Laurence ^b   Trunet, Patrick ^b  

^a HÔPITAL TENON   (France)

^b Oncology Global Development   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; LATEX; MONOCLONAL ANTIBODY; OMALIZUMAB;

ADULT; ALLERGY; BLOOD; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLOVE; HEALTH CARE PERSONNEL; HUMAN; LETTER; MALE; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; PRICK TEST; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN ALLERGY; SKIN MANIFESTATION; SKIN TEST; SURGICAL GLOVE; TREATMENT OUTCOME;

EID: 1142297324     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2003.11.020     Document Type: Letter

References (5)

1. Agarwal S, Gawkrodger DJ. Latex allergy: a health care problem of epidemic proportions. Eur J Dermatol 2002;12:311-5.
2. Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61.
3. Ädelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253-9.
4. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. Arch Ophthalmol 1990;108:84-8.
5. Leynadier F, Herman D, Vervloet D, Andre C. Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers. J Allergy Clin Immunol 2000;106:585-90.